Ask AI
ProCE Banner Activity

Emerging Strategies for Better Endometrial Cancer Care: Answers to Frequently Asked Questions

Clinical Thought

Read this commentary of expert answers to audience questions on current and emerging treatment strategies for patients with endometrial cancer.

Released: December 29, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Eisai, Gilead Sciences, Inc., and Merck Sharp & Dohme LLC.

Eisai

Gilead Sciences, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with endometrial cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze current recommendations for molecular testing in endometrial cancer, including the rationale, patient counseling approaches, optimal test ordering strategies, and clinical implications of key biomarkers

  • Compare and contrast the efficacy, safety, and appropriate patient selection criteria for available and emerging immune checkpoint inhibitor-based and targeted therapies in endometrial cancer management

  • Analyze the latest clinical data on emerging antibody-drug conjugates (ADCs) for advanced endometrial cancer, examining their mechanisms of action, efficacy, safety profiles, and potential impact on treatment strategies

  • Examine key factors contributing to care disparities in endometrial cancer patients, with a focus on Black, transgender, and underserved populations, and critically evaluate strategies to address these disparities in clinical practice

Disclosure

Primary Author

Nicoletta Colombo, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, BioNTech, Eisai, Genmab, Gilead, GSK, ImmunoGen, Lilly, MSD, Nuvation Bio, OncXerna, Regeneron, Seagen.

Domenica Lorusso, MD, PhD, Prof: consultant/advisor/speaker: AbbVie, AstraZeneca, Corcept, Daiichi Sankyo, Genentech, Genmab, GSK, Merck Sharp & Dohme, Sutro; researcher: AstraZeneca, Clovis Oncology, Corcept, Genmab, GSK, ImmunoGen, Incyte, Merck Sharp & Dohme, Novartis, PharmaMar, Roche, Seagen.